The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy

Reliability, concurrent validity, and minimal clinically important differences from a multicenter study

Craig M McDonald, Erik K Henricson, R. Ted Abresch, Julaine Florence, Michelle Eagle, Eduard Gappmaier, Allan M. Glanzman, Robert Spiegel, Jay Barth, Gary Elfring, Allen Reha, Stuart W. Peltz

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

Introduction: An international clinical trial enrolled 174 ambulatory males ≥5 years old with nonsense mutation Duchenne muscular dystrophy (nmDMD). Pretreatment data provide insight into reliability, concurrent validity, and minimal clinically important differences (MCIDs) of the 6-minute walk test (6MWT) and other endpoints. Methods: Screening and baseline evaluations included the 6-minute walk distance (6MWD), timed function tests (TFTs), quantitative strength by myometry, the PedsQL, heart rate-determined energy expenditure index, and other exploratory endpoints. Results: The 6MWT proved feasible and reliable in a multicenter context. Concurrent validity with other endpoints was excellent. The MCID for 6MWD was 28.5 and 31.7 meters based on 2 statistical distribution methods. Conclusions: The ratio of MCID to baseline mean is lower for 6MWD than for other endpoints. The 6MWD is an optimal primary endpoint for Duchenne muscular dystrophy (DMD) clinical trials that are focused therapeutically on preservation of ambulation and slowing of disease progression.

Original languageEnglish (US)
Pages (from-to)357-368
Number of pages12
JournalMuscle and Nerve
Volume48
Issue number3
DOIs
StatePublished - Sep 2013

Fingerprint

Duchenne Muscular Dystrophy
Reproducibility of Results
Multicenter Studies
Clinical Trials
Statistical Distributions
Nonsense Codon
Energy Metabolism
Walking
Disease Progression
Heart Rate
Walk Test
Minimal Clinically Important Difference

Keywords

  • 6-minute walk test
  • Ambulation
  • Duchenne muscular dystrophy
  • Energy expenditure index
  • Muscular dystrophy
  • Myometry
  • Natural history
  • PedsQL
  • Timed function test

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)
  • Physiology

Cite this

The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy : Reliability, concurrent validity, and minimal clinically important differences from a multicenter study. / McDonald, Craig M; Henricson, Erik K; Abresch, R. Ted; Florence, Julaine; Eagle, Michelle; Gappmaier, Eduard; Glanzman, Allan M.; Spiegel, Robert; Barth, Jay; Elfring, Gary; Reha, Allen; Peltz, Stuart W.

In: Muscle and Nerve, Vol. 48, No. 3, 09.2013, p. 357-368.

Research output: Contribution to journalArticle

McDonald, Craig M ; Henricson, Erik K ; Abresch, R. Ted ; Florence, Julaine ; Eagle, Michelle ; Gappmaier, Eduard ; Glanzman, Allan M. ; Spiegel, Robert ; Barth, Jay ; Elfring, Gary ; Reha, Allen ; Peltz, Stuart W. / The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy : Reliability, concurrent validity, and minimal clinically important differences from a multicenter study. In: Muscle and Nerve. 2013 ; Vol. 48, No. 3. pp. 357-368.
@article{1e1d448a6dd24367b7e051a1c53d2e32,
title = "The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: Reliability, concurrent validity, and minimal clinically important differences from a multicenter study",
abstract = "Introduction: An international clinical trial enrolled 174 ambulatory males ≥5 years old with nonsense mutation Duchenne muscular dystrophy (nmDMD). Pretreatment data provide insight into reliability, concurrent validity, and minimal clinically important differences (MCIDs) of the 6-minute walk test (6MWT) and other endpoints. Methods: Screening and baseline evaluations included the 6-minute walk distance (6MWD), timed function tests (TFTs), quantitative strength by myometry, the PedsQL, heart rate-determined energy expenditure index, and other exploratory endpoints. Results: The 6MWT proved feasible and reliable in a multicenter context. Concurrent validity with other endpoints was excellent. The MCID for 6MWD was 28.5 and 31.7 meters based on 2 statistical distribution methods. Conclusions: The ratio of MCID to baseline mean is lower for 6MWD than for other endpoints. The 6MWD is an optimal primary endpoint for Duchenne muscular dystrophy (DMD) clinical trials that are focused therapeutically on preservation of ambulation and slowing of disease progression.",
keywords = "6-minute walk test, Ambulation, Duchenne muscular dystrophy, Energy expenditure index, Muscular dystrophy, Myometry, Natural history, PedsQL, Timed function test",
author = "McDonald, {Craig M} and Henricson, {Erik K} and Abresch, {R. Ted} and Julaine Florence and Michelle Eagle and Eduard Gappmaier and Glanzman, {Allan M.} and Robert Spiegel and Jay Barth and Gary Elfring and Allen Reha and Peltz, {Stuart W.}",
year = "2013",
month = "9",
doi = "10.1002/mus.23905",
language = "English (US)",
volume = "48",
pages = "357--368",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy

T2 - Reliability, concurrent validity, and minimal clinically important differences from a multicenter study

AU - McDonald, Craig M

AU - Henricson, Erik K

AU - Abresch, R. Ted

AU - Florence, Julaine

AU - Eagle, Michelle

AU - Gappmaier, Eduard

AU - Glanzman, Allan M.

AU - Spiegel, Robert

AU - Barth, Jay

AU - Elfring, Gary

AU - Reha, Allen

AU - Peltz, Stuart W.

PY - 2013/9

Y1 - 2013/9

N2 - Introduction: An international clinical trial enrolled 174 ambulatory males ≥5 years old with nonsense mutation Duchenne muscular dystrophy (nmDMD). Pretreatment data provide insight into reliability, concurrent validity, and minimal clinically important differences (MCIDs) of the 6-minute walk test (6MWT) and other endpoints. Methods: Screening and baseline evaluations included the 6-minute walk distance (6MWD), timed function tests (TFTs), quantitative strength by myometry, the PedsQL, heart rate-determined energy expenditure index, and other exploratory endpoints. Results: The 6MWT proved feasible and reliable in a multicenter context. Concurrent validity with other endpoints was excellent. The MCID for 6MWD was 28.5 and 31.7 meters based on 2 statistical distribution methods. Conclusions: The ratio of MCID to baseline mean is lower for 6MWD than for other endpoints. The 6MWD is an optimal primary endpoint for Duchenne muscular dystrophy (DMD) clinical trials that are focused therapeutically on preservation of ambulation and slowing of disease progression.

AB - Introduction: An international clinical trial enrolled 174 ambulatory males ≥5 years old with nonsense mutation Duchenne muscular dystrophy (nmDMD). Pretreatment data provide insight into reliability, concurrent validity, and minimal clinically important differences (MCIDs) of the 6-minute walk test (6MWT) and other endpoints. Methods: Screening and baseline evaluations included the 6-minute walk distance (6MWD), timed function tests (TFTs), quantitative strength by myometry, the PedsQL, heart rate-determined energy expenditure index, and other exploratory endpoints. Results: The 6MWT proved feasible and reliable in a multicenter context. Concurrent validity with other endpoints was excellent. The MCID for 6MWD was 28.5 and 31.7 meters based on 2 statistical distribution methods. Conclusions: The ratio of MCID to baseline mean is lower for 6MWD than for other endpoints. The 6MWD is an optimal primary endpoint for Duchenne muscular dystrophy (DMD) clinical trials that are focused therapeutically on preservation of ambulation and slowing of disease progression.

KW - 6-minute walk test

KW - Ambulation

KW - Duchenne muscular dystrophy

KW - Energy expenditure index

KW - Muscular dystrophy

KW - Myometry

KW - Natural history

KW - PedsQL

KW - Timed function test

UR - http://www.scopus.com/inward/record.url?scp=84883050768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883050768&partnerID=8YFLogxK

U2 - 10.1002/mus.23905

DO - 10.1002/mus.23905

M3 - Article

VL - 48

SP - 357

EP - 368

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 3

ER -